



UNIVERSITY OF LEEDS

This is a repository copy of *Affimer-based impedimetric biosensors for fibroblast growth factor receptor 3 (FGFR3): a novel tool for detection and surveillance of recurrent bladder cancer*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/166151/>

Version: Supplemental Material

Article:

Thangsunan, P, Lal, N, Tiede, C et al. (8 more authors) (2021) Affimer-based impedimetric biosensors for fibroblast growth factor receptor 3 (FGFR3): a novel tool for detection and surveillance of recurrent bladder cancer. *Sensors and Actuators B: Chemical*, 326. 128829. ISSN 0925-4005

<https://doi.org/10.1016/j.snb.2020.128829>

© 2020 Elsevier B.V. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDeriv (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary Information

Affimer-based impedimetric biosensors for fibroblast growth factor receptor 3 (FGFR3): a novel tool for detection and surveillance of recurrent bladder cancer

Pattanapong Thangsunan^{a, g}, Nidhi Lal^b, Christian Tiede^{c, d}, Sophie Moul^b,
James I. Robinson^e, Margaret A. Knowles^f, Peter G. Stockley^c, Paul A. Beales^b,
Darren C. Tomlinson^{c, d}, Michael J. McPherson^{c, d} and Paul A. Millner^{a, *}

^a *School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom*

^b *School of Chemistry, Faculty of Engineering and Physical Sciences, University of Leeds, Leeds, United Kingdom*

^c *School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom*

^d *BioScreening Technology Group, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom*

^e *Leeds Institute of Rheumatic and Musculoskeletal Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom*

^f *Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom*

^g *Bioanalysis Group, Chemical Metrology and Biometry Department, National Institute of Metrology, Klong 5, Klong Luang, Pathum Thani, Thailand*

^{*} *Corresponding author at: School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, United Kingdom*

Email address: p.a.millner@leeds.ac.uk (P. A. Millner)




Figure S1 LC-MS spectra showing the successful biotinylation of FGFR3-21 Affimer proteins. (A) non-biotinylated FGFR3-21 Affimers showed two distinct peaks, which represent (a) monomeric forms and (b) dimeric forms. (B) biotinylated FGFR3-21 Affimers showed a peak representing (c) biotinylated monomeric forms.




Figure S2 SPR sensorgram of FGFR3-8 Affimer interaction with FGFR3 protein. The FGFR3-8 Affimers were immobilised onto a streptavidin-coated sensor chip before being challenged by FGFR3 at concentrations from 0 to 1000 nM. In this case, the association phase was run for 180 s, followed by 900 s of the dissociation phase.




Figure S3 SPR data fitting with a one-site specific model. (A), fitting for FGFR3-14 Affimer and (B), for FGFR3-21 Affimer. The black lines represent experimental data from SPR whilst the red lines show the fitting results which are overlaid. The data from association phase were fitted with a one-site specific binding model whereas the data from dissociation phase was analysed using a one-phase decay exponential model.

Table S1 Fitting SPR data from a one-site binding model. Parameters were determined from the data in Figure S3.

Affimer clones	FGFR3-14	FGFR3-21
k_{on} ($M^{-1} s^{-1}$)	1.60×10^8	4.49×10^8
k_{off} (s^{-1})	5.24×10^{-2}	8.31×10^{-3}
K_D (M)	3.27×10^{-10}	1.85×10^{-11}
R^2	0.955	0.976
χ^2	1.610	1.071




Figure S4 Nyquist plots showing the stability of baseline before a sensor chip was tested with FGFR3 protein. Four consecutive impedance measurements were performed after the sensor was incubated in 100 mM PBS pH 7.2 for 1 h. The measurement was performed in a solution of 100 mM PBS pH 7.2 containing 10 mM $K_3Fe(CN)_6/K_4Fe(CN)_6$ over a range of frequencies from 2.5 kHz to 250 mHz.






Figure S5 Calibration curves of the Affimer-based impedimetric biosensors for detecting FGFR3 in PBS. Three blocking agents, (A), 6.7 μM BSA; (B), 2x casein blocking buffer from Sigma-Aldrich and (C), 0.2 mg/ml sodium caseinate, were tested for minimising non-specific binding effects. The EIS was performed in 10 mM $\text{K}_3\text{Fe}(\text{CN})_6/\text{K}_4\text{Fe}(\text{CN})_6$ solution. Data are means \pm SEM (n=3).






Figure S6 Calibration curves of the Affimer-based impedimetric biosensors for detecting FGFR3 in PBS. The sensors were blocked with 6.7 μM BSA prior to Affimer attachment. Three concentration of Affimers, (A), 0.3 μM ; (B), 1 μM and (C), 3 μM , were tested for the optimal condition. The EIS was performed in 10 mM $\text{K}_3\text{Fe}(\text{CN})_6/\text{K}_4\text{Fe}(\text{CN})_6$ solution. Data are means \pm SEM (n=3).